Shots:
- The company presented new analysis data from the P-III EXPLORER-HCM trial assessing mavacamten in patients with oHCM that tested the impact of the therapy on patients’ health status i.e symptoms, function, and QoL
- The company unveils the interim results from MAVA-LTE, 5yrs. extension study of the EXPLORER-HCM. The study demonstrated improvement in LVOT gradients, diastolic function, NT-proBNP, and symptoms and was well tolerated
- The company also presented real-world data analysis measuring the clinical & economic burden of oHCM in the US. Mavacamten is an oral, allosteric modulator of cardiac myosin for patients with oHCM
Click here to read full press release/ article | Ref: PRNewswire | Image: StraitTimes
The post BMS Presents Clinical and RWE Data of Mavacamten for Obstructive Hypertrophic Cardiomyopathy at ACC 2021 first appeared on PharmaShots.
